Structural determinants and genetic modifications enhance BMP2 stability and extracellular secretion

The short half‐life and use of recombinant bone morphogenetic protein (BMP)2 in large doses poses major limitations in the clinic. Events regulating posttranslational processing and degradation of BMP2 in situ, linked to its secretion, have not been understood. Toward identifying mechanisms regulati...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	FASEB bioAdvances 2019-03, Vol.1 (3), p.180-190
Hauptverfasser:	Khattar, Vinayak, Lee, Joo Hyoung, Wang, Hong, Bastola, Soniya, Ponnazhagan, Selvarangan
Format:	Artikel
Sprache:	eng
Schlagworte:	Bioavailability Biological activity BMP2 Bone cancer Bone morphogenetic protein 2 Bone morphogenetic proteins Fractures Intracellular Ligands Lysine Mutagenesis Phosphorylation Proprotein convertases proteasomal degradation Proteasomes Protein expression protein turnover Proteins Retention Secretion Skin & tissue grafts Ubiquitin Ubiquitination
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!